2024 Glufosfamide threshold brain delivery

Glufosfamide threshold brain delivery

Author: qiwm

August undefined, 2024

WebJul 28, 2007 · Glufosfamide (Threshold Pharmaceuticals, Redwood City, CA) is a new cytotoxic alkylating agent prodrug in which isophosphoramide mustard (IPM) is glycosidically linked to β-D-glucose. ... Patients were excluded from the study if they had previously received gemcitabine, if they had symptomatic brain metastases, radiation therapy … WebDec 28, 2006 · Glufosfamide was generally well tolerated in combination with gemcitabine with no new unexpected adverse events. "We are pleased with these encouraging top-line results and look forward next year to additional six- and twelve-month survival data from this clinical trial," said Barry Selick, Ph.D., Threshold's chief executive officer.

The chemomodulatory effects of glufosfamide on docetaxel

WebSep 27, 2007 · The median survival of patients who were treated with glufosfamide was 105 days (3.45 months) versus 84 days (2.76 months) for the patients who received … WebApr 6, 2000 · Arm II: Patients receive glufosfamide as in arm I. Patients are hydrated with excess physiological saline solution 4 hours before and for 3 hours after treatment with glufosfamide. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. ... Conditions: Brain and Central Nervous System Tumors . … tracey wickham today

Threshold Pharmaceuticals, Inc. Announces Top-Line Phase 2 …

WebJan 31, 2005 · Our data suggests that a disfunction in glutamate-glutamine cycle in the brain may play a role in the pathophysiology of schizophrenia. Elevated … WebGlufosfamide is a novel small molecule that has been evaluated by Threshold in a Phase 3 clinical trial and multiple Phase 2 clinical trials. Under the agreement, Eleison is … WebOct 3, 2006 · The Phase III trial will evaluate approximately 300 previously treated patients with locally advanced and/or metastatic pancreatic cancer who receive best supportive … tracey wiese anchorage

Safety and Efficacy Study of Glufosfamide in Ovarian Cancer

Strategies for delivering therapeutics across the …

WebMar 19, 2008 · Indication. Investigated for use/treatment in pancreatic cancer, solid tumors, breast cancer, colorectal cancer, brain cancer, lung cancer, ovarian cancer, and sarcoma. Build, train, & validate predictive machine-learning models with structured datasets. See how. Contraindications & Blackbox Warnings. WebOct 3, 2006 · October 3, 2006. Threshold Pharmaceuticals announced that under the FDA has granted orphan drug designation to the company's product candidate, glufosfamide, for the treatment of pancreatic cancer. Orphan drug designation is intended to encourage research and development of new therapies for diseases that affect fewer than 200,000 … tracey wigfield weddingWebMay 20, 2008 · 10591 Background: Glufosfamide is glucose linked to isophosphoramide mustard, the active metabolite of ifosfamide. Ifosfamide is known to have activity in soft tissue sarcoma. The objectives of this study are to evaluate the safety and efficacy of GLU in patients (pts) with soft tissue sarcoma. Methods: This 1-stage phase 2 study planned to … tracey wigfield imdb

"WebJun 2, 2006 · We are hopeful that, if successful in this trial, glufosfamide will give patients another treatment option against this deadly cancer." Phase 3 Study Details The pivotal Phase 3 trial is a randomized, open-label, multi-center trial designed to evaluate the efficacy and safety of glufosfamide compared with best supportive care (BSC) in patients ... " - Glufosfamide threshold brain delivery

Glufosfamide threshold brain delivery

Threshold Pharmaceuticals, Inc. Announces Top-Line Phase 2 …

WebFeb 2, 2005 · The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine. Detailed Description: This study, TH-CR … WebMar 2, 2007 · To evaluate the safety of weekly glufosfamide dosing in subjects with ovarian cancer as compared with every 21-day dosing. Secondary objectives: To evaluate the efficacy of glufosfamide in subjects with ovarian cancer as measured by objective response rate, duration of response, progression-free survival, and overall survival.

Did you know?

WebIt had been in phase III clinical trials by Threshold for this indication, but discontinued later. Glufosfamide was originally developed by Baxter, then licensed to Threshold with exclusive wordwide rights in 2003. ... Glufosfamide （Free Acid/Base）Parameters： MW: H D: H A: FRB * PSA * cLogP * 383.16: 6: 9: 11: 150-1.382±0.602 ... WebIn this way, glufosfamide targets cancer cells while reducing toxicity to normal cells. Glufosfamide has been evaluated in more than 450 patients in multiple clinical studies …

WebJan 18, 2008 · Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that … WebDec 1, 2003 · Discussion. Glufosfamide showed a low hematological and non-hematological toxicity profile in GBM patients. The relatively large volume that was administrated in a short time (1000 ml in 60 min) did not cause increased edema or neurological deterioration during or shortly after the infusion, events that have been …

Glufosfamide, being a conjugate of glucose and active alkylating moiety of ifosfamide, has the better cell permeability than the parent compound — ifosfamide — or its metabolites. Glufosfamide utilizes the normal cell glucose transport mechanism (a sodium-dependent glucose/sodium co-transporter) for its own transport into the cell. And the glucose uptake mechanism is grossly overexpressed and upregulated in certain cancer cell lines, especially pan… WebSep 28, 2006 · Last month the Company announced that it had completed enrollment in a pivotal phase 3 clinical trial evaluating glufosfamide for the potential second-line treatment of pancreatic cancer and a phase 2 clinical trial evaluating glufosfamide in combination with gemcitabine for the potential first-line treatment of pancreatic cancer.

WebMay 3, 2004 · OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms: Arm I: Patients receive glufosfamide IV over 1 hour on day 1. Arm II: Patients receive glufosfamide as in arm I. Patients are hydrated with excess physiological saline solution 4 hours before and for 3 hours after treatment with …

WebBrain and Central Nervous System Tumors (1) Carcinoma, Small Cell Lung (1) Lung Cancer (1) ... Threshold Pharmaceuticals (3) Sign Up. Intervention New. glufosfamide (9) fluorouracil (1) gemcitabine (1) Study Results. Has … thermoworks thermopop targetWebMar 1, 2024 · Achieving sufficient delivery across the blood–brain barrier is a key challenge in the development of drugs to treat central nervous system (CNS) disorders. thermoworks thermopop tx-3100WebApr 2, 2024 · glufosfamide: brain and CNS system tumors: NCT00014300: phase II (completed) glufosfamide: pancreatic cancer: NCT00005053: phase II (completed) glufosfamide: lung cancer: ... macrophage-based targeting strategies have also been employed for brain delivery to reduce inflammation to alleviate Parkinson’s disease … tracey wigginsWebThere was an 18% increase in overall survival for glufosfamide that was not statistically significant: hazard ratio (HR) 0.85 (95% confidence interval (CI) 0.66-1.08, p=0.19). … thermoworks thermopop tx-3100-xxWebNov 5, 2024 · Intermittent theta-burst stimulation (iTBS) is an FDA-approved neuromodulation therapy for treating major depressive disorder (MDD). Standard iTBS … tracey wigginton murder caseWebMar 1, 2007 · 1. To evaluate the efficacy of glufosfamide in subjects with advanced soft tissue sarcoma as measured by objective response rate. Secondary Objectives: To … thermoworks thermopop thermometerWebGlufosfamide is an alkylating agent consisting of iphosphoramide mustard conjugated to glucose that is currently included in clinical studies of pancreatic cancer. We studied the … tracey wigginton book